Clinical application of molecular pathology in sarcomas

被引:9
作者
Romeo, Salvatore [1 ]
Tos, Angelo P. Dei [1 ]
机构
[1] Gen Hosp Treviso, Dept Pathol, I-31100 Treviso, Italy
关键词
molecular pathology; oncology; sarcoma; tailored treatment; translocation; GASTROINTESTINAL STROMAL TUMORS; SOFT-TISSUE SARCOMAS; SSX FUSION TYPE; SYNOVIAL SARCOMA; PHASE-II; IMATINIB; DOCETAXEL; CANCER; GEMCITABINE; THERAPY;
D O I
10.1097/CCO.0b013e328347b9be
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review This review is intended to highlight the clinical application of molecular pathology as a tool for diagnostic accuracy and prognostic and predictive use and finally to discover novel molecular therapeutic targets. Recent findings We are living an exciting era in sarcomas' therapy. This is the result of overcoming two crucial obstacles: lack of effective and specific drugs; lack of specific therapeutic regimen for distinct clinical entities. As new specific drugs have become available, it has become clear that an accurate diagnosis is the prerequisite for a specific therapy. This approach has been successfully applied to gastrointestinal stromal tumor and is now also being used in other sarcomas. The more recent findings are hereby reviewed. Summary The inclusion of the molecular pathology in the diagnostic surgical pathology is instrumental for the application of molecularly tailored therapy. However, the degree of complexity of this approach requires additional caution in the data interpretation and in the reproducibility of the results. As molecular knowledge is improving and more sophisticated and powerful techniques are going to be routinely used, the success rate in treating sarcomas is expected to significantly increase.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 45 条
[21]   Molecular correlates of imatinib resistance in gastrointestinal stromal tumors [J].
Heinrich, Michael C. ;
Corless, Christopher L. ;
Blanke, Charles D. ;
Demetri, George D. ;
Joensuu, Heikki ;
Roberts, Peter J. ;
Eisenberg, Burton L. ;
von Mehren, Margaret ;
Fletcher, Christopher D. M. ;
Sandau, Katrin ;
McDougall, Karen ;
Ou, Wen-bin ;
Chen, Chang-Jie ;
Fletcher, Jonathan A. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4764-4774
[22]   Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial [J].
Hensley, ML ;
Maki, R ;
Venkatraman, E ;
Geller, G ;
Lovegren, M ;
Aghajanian, C ;
Sabbatini, P ;
Tong, W ;
Barakat, R ;
Spriggs, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2824-2831
[23]  
HOSTEIN I, 2011, J GASTROENTEROL
[24]   Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [J].
Joensuu, H ;
Roberts, PJ ;
Sarlomo-Rikala, M ;
Andersson, LC ;
Tervahartiala, P ;
Tuveson, D ;
Silberman, SL ;
Capdeville, R ;
Dimitrijevic, S ;
Druker, B ;
Demetri, GD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1052-1056
[25]   SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma [J].
Kawai, A ;
Woodruff, J ;
Healey, JH ;
Brennan, MF ;
Antonescu, CR ;
Ladanyi, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (03) :153-160
[26]  
Ladanyi M, 2002, CANCER RES, V62, P135
[27]   The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 [J].
Ladanyi, M ;
Lui, MY ;
Antonescu, CR ;
Krause-Boehm, A ;
Meindl, A ;
Argani, P ;
Healey, JH ;
Ueda, T ;
Yoshikawa, H ;
Meloni-Ehrig, A ;
Sorensen, PHB ;
Mertens, F ;
Mandahl, N ;
van den Berghe, H ;
Sciot, R ;
Dal Cin, P ;
Bridge, J .
ONCOGENE, 2001, 20 (01) :48-57
[28]   Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial [J].
Le Cesne, A ;
Blay, JY ;
Judson, I ;
Van Oosterom, A ;
Verweij, J ;
Radford, J ;
Lorigan, P ;
Rodenhuis, S ;
Ray-Coquard, I ;
Bonvalot, S ;
Collin, F ;
Jimeno, J ;
Di Paola, E ;
Van Glabbeke, M ;
Nielsen, OS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :576-584
[29]   Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas [J].
Maki, Robert G. ;
Wathen, J. Kyle ;
Patel, Shreyaskumar R. ;
Priebat, Dennis A. ;
Okuno, Scott H. ;
Samuels, Brian ;
Fanucchi, Michael ;
Harmon, David C. ;
Schuetze, Scott M. ;
Reinke, Denise ;
Thall, Peter F. ;
Benjamin, Robert S. ;
Baker, Laurence H. ;
Hensley, Martee L. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2755-2763
[30]   Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and future [J].
Maki, Robert G. .
ONCOLOGIST, 2007, 12 (08) :999-1006